Opportunity Information: Apply for RFA AR 11 004
Apply for RFA AR 11 004
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitve Revision Award (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Feb 26, 2010 and posted on Feb 26, 2010.
- Applicants must submit their applications by Aug 4, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $650,000.00 in funding.
- Eligible applicants include: State governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Public housing authorities/Indian housing authorities Private institutions of higher education Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIAMS Accelerating Research Translation (ART) Competitive Revision Award (R01) opportunity (RFA-AR-11-004) is a National Institutes of Health funding announcement designed to push promising tissue engineering and regenerative medicine (TE/RM) work in musculoskeletal and skin conditions closer to the clinic. The central goal is to provide additional, targeted support to investigators who already hold active NIAMS-funded parent awards so they can run the kind of preclinical studies that are often the last major step before a first-in-human trial. In practice, this announcement is aimed at bridging the gap between strong lab-stage results and the specific evidence package needed to justify Phase I/II clinical testing.
A defining feature of this program is its emphasis on large animal preclinical studies, rather than earlier exploratory work in small animals. NIAMS is explicitly looking for studies with near-term translational relevance, meaning the work should be positioned to immediately inform or enable human trials in musculoskeletal or skin TE/RM. The announcement highlights three main types of outcomes NIAMS wants these revisions to deliver: (1) generating the key data required to support Phase I/II clinical trials, (2) demonstrating preclinical efficacy of a TE/RM therapy in a model that is clinically meaningful for musculoskeletal or skin indications, and/or (3) developing or refining large animal models that can directly accelerate TE/RM programs into Phase I/II clinical testing. By contrast, early translational studies limited to rodents or rabbits are considered non-responsive, which signals that NIAMS expects applicants to already be beyond proof-of-concept and ready for more clinically predictive testing.
From a funding and mechanism standpoint, this opportunity uses the NIH revision mechanism to an R01, described as revision support that was formerly referred to as a competing supplement. That means the application is not a brand-new standalone R01; it is a competitive request to add scope and funds to an existing, active NIAMS R01 (with related companion opportunities running in parallel for P01 and P50 awards under a separate FOA, RFA-AR-11-005, with the same scientific scope). NIAMS anticipated a relatively small number of total awards across both announcements, reflecting the higher cost and complexity typical of large animal studies. Specifically, NIAMS planned to commit about $1,000,000 in total costs in FY 2011 to make roughly 1 to 3 ART awards across RFA-AR-11-004 and RFA-AR-11-005 combined, with an award ceiling listed at $650,000. As with most NIH RFAs, awards were contingent on the availability of funds and the submission of meritorious applications.
The eligible applicant list is broad and includes many common NIH applicant categories such as public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), for-profit entities (including small businesses and other for-profit organizations), state and local governments, U.S. territories or possessions, tribal governments and tribal organizations, and certain school districts and special districts. The eligibility notes also reference several institution types and communities NIAMS explicitly recognizes as eligible, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, and foreign (non-U.S.) entities. At the same time, the practical eligibility constraint embedded in the purpose statement is that applicants must have an active NIAMS parent grant (R01 for this specific FOA) that can appropriately support a competitive revision focused on large animal translational TE/RM work.
Key administrative details place this as an archived historical opportunity: it was posted and created on February 26, 2010, with an original and current closing date of August 4, 2010, and an archive date of September 4, 2010. The CFDA number associated with the program area is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), and there is no cost sharing or matching requirement. For applicants at the time, the full announcement and instructions were provided through the NIH Grants Guide, and NIH Office of Extramural Research contact points were listed for technical access issues.
FAQs: NIAMS Accelerating Research Translation (ART) Competitive Revision Award (R01) - RFA-AR-11-004
What is the NIAMS ART Competitive Revision Award (R01) opportunity?
It is a National Institutes of Health (NIH) funding announcement from NIAMS intended to accelerate promising tissue engineering and regenerative medicine (TE/RM) research for musculoskeletal and skin conditions toward clinical use. The focus is on providing targeted, additional support so investigators can complete preclinical studies that are often the final major step before first-in-human trials.
What is the main goal of this program?
The central goal is to bridge the gap between strong laboratory-stage results and the specific preclinical evidence package needed to justify Phase I/II clinical testing in humans for musculoskeletal or skin TE/RM therapies.
What kinds of studies does NIAMS emphasize under this announcement?
The program emphasizes large animal preclinical studies with near-term translational relevance, meaning the work should be positioned to immediately inform or enable Phase I/II human trials in musculoskeletal or skin TE/RM.
What outcomes is NIAMS looking for these competitive revisions to deliver?
NIAMS highlights three main types of expected outcomes: (1) generating key data required to support Phase I/II clinical trials, (2) demonstrating preclinical efficacy of a TE/RM therapy in a clinically meaningful model for musculoskeletal or skin indications, and/or (3) developing or refining large animal models that can directly accelerate TE/RM programs into Phase I/II clinical testing.
Are small animal studies allowed under this opportunity?
Early translational studies limited to rodents or rabbits are described as non-responsive. This indicates NIAMS expects applicants to be beyond proof-of-concept and ready for more clinically predictive testing, particularly in large animal models.
Is this a new, standalone R01 grant application?
No. This opportunity uses the NIH revision mechanism to an R01 (revision support formerly referred to as a competing supplement). It is a competitive request to add scope and funds to an existing, active NIAMS-funded parent R01, rather than a brand-new standalone R01.
Who is practically eligible to apply?
While the eligible applicant categories are broad, a key practical requirement is that the applicant must have an active NIAMS parent grant that can support a competitive revision. For this specific FOA (RFA-AR-11-004), the parent award is an NIAMS R01.
What types of organizations are listed as eligible applicants?
The eligibility list includes public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), for-profit entities (including small businesses and other for-profit organizations), state and local governments, U.S. territories or possessions, tribal governments and tribal organizations, and certain school districts and special districts.
Does NIAMS mention eligibility for specific institution types or communities?
Yes. The eligibility notes reference that NIAMS recognizes several institution types and communities as eligible, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, and foreign (non-U.S.) entities.
Is there a related FOA for other parent award mechanisms besides R01?
Yes. A related companion opportunity is referenced for P01 and P50 parent awards under a separate FOA, RFA-AR-11-005, with the same scientific scope.
How much funding was NIAMS planning to commit, and how many awards were anticipated?
NIAMS planned to commit about $1,000,000 in total costs in FY 2011 to make roughly 1 to 3 ART awards across RFA-AR-11-004 and RFA-AR-11-005 combined, reflecting the higher cost and complexity of large animal studies.
What is the award ceiling mentioned in the announcement?
The award ceiling listed for this opportunity is $650,000.
Are awards guaranteed if an application is submitted?
No. As with most NIH RFAs, awards were contingent on the availability of funds and the submission of meritorious applications.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the CFDA number associated with this program area?
The CFDA number listed is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).
When was this opportunity posted, and what were the key dates?
The opportunity was posted and created on February 26, 2010. The original and current closing date was August 4, 2010, and the archive date was September 4, 2010.
Is this an active funding opportunity today?
Based on the provided dates and the archive status, this is an archived historical opportunity (closed August 4, 2010, and archived September 4, 2010).
Where were the full announcement and application instructions provided?
For applicants at the time, the full announcement and instructions were provided through the NIH Grants Guide.
Who was listed for technical help with accessing the NIH systems or materials?
NIH Office of Extramural Research contact points were listed for technical access issues.
What research areas and conditions are in scope?
The scope is TE/RM research aimed at musculoskeletal and skin conditions, with an emphasis on translational preclinical work intended to move those approaches closer to Phase I/II clinical testing.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitive Revision Award (P01 and P50)
Previous opportunity: Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage I(CADET I) (P50)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 11 004
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 11 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitive Revision Award (P01 and P50) Apply for RFA AR 11 005 Funding Number: RFA AR 11 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Indo U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03) Apply for PA 10 115 Funding Number: PA 10 115 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Support Establishment and Sustainability of Medical Waste Management Systems in the Republic of Kenya under the President s Emergency plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10135 Funding Number: CDC RFA PS10 10135 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Production Of Human Proteins To Be Used For Generating Affinity Reagents (U01) Apply for RFA RM 10 007 Funding Number: RFA RM 10 007 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Providing a Comprehensive Continuum of HIV/AIDS Care and Treatment Services in the Democratic Republic of Congo Under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10132 Funding Number: CDC RFA PS10 10132 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| ARRA Equipment to Enhance Training for Health Professionals Preventive Medicine Residency Program Apply for HRSA 10 180 Funding Number: HRSA 10 180 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Large Scale Production of Perturbagen Induced Cellular Signatures (U54) Apply for RFA RM 10 003 Funding Number: RFA RM 10 003 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM Apply for DHAPPBAA10 001 Funding Number: DHAPPBAA10 001 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| APHIAplus PROGRAM DESCRIPTION Apply for RFA 623 10 000009 Funding Number: RFA 623 10 000009 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $76,000,000 |
| MCH Research Network on Pregnancy Related Care Apply for HRSA 10 088 Funding Number: HRSA 10 088 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season (U18) Apply for RFA IP 10 007 Funding Number: RFA IP 10 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data, NCIPC Apply for CE08 80203CONT10 Funding Number: CE08 80203CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Maintaining Collection of National Violent Death Reporting System (NVDRS) Data, NCIPC Apply for CE07 70404CONT10 Funding Number: CE07 70404CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Development of the National Violent Death Reporting System (NVDRS), NCIPC Apply for CE09 90402CONT10 Funding Number: CE09 90402CONT10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Promoting Extensive Implementation of Quality Prevention of Mother to Child Transmission (PMTCT) Activities in the Republic of Uganda Apply for CDC RFA PS04 230 Funding Number: CDC RFA PS04 230 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Strengthening Public Health Capacity and Strategic Information Systems through Cooperation with the Joint United Nations Programme on HIV/AIDS (UNAIDS) under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10157 Funding Number: CDC RFA PS10 10157 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Providing Capacity Building Assistance to Governmental and Indigenous Organizations in order to Improve the Delivery of HIV/AIDS Services in the Democratic Republic of Congo Under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10101 Funding Number: CDC RFA PS10 10101 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Family Centered Substance Abuse Treatment Grants for Adolescents and their Families Apply for TI 10 002 Funding Number: TI 10 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Improving availability of safe blood transfusion services through a mentoring technical assistance (TA) relationship with The Nigerian National Blood Transfusion Service, to ensure a sustainable quality management system in the Federal Republic of Ni Apply for CDC RFA PS10 1039 Funding Number: CDC RFA PS10 1039 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Strengthening the Capacity of the Republican AIDS Center to implement HIV Programs in the Kyrgyz Republic under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 10163 Funding Number: CDC RFA PS10 10163 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 11 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.